Loading...
XNAS
SWKHL
Market cap174mUSD
May 16, Last price  
25.45USD
1D
-0.20%
1Q
1.39%
Name

SWK Holdings Corp

Chart & Performance

D1W1MN
No data to show
P/E
23.15
P/S
6.94
EPS
1.10
Div Yield, %
6.63%
Shrs. gr., 5y
-0.72%
Rev. gr., 5y
7.91%
Revenues
45m
+19.14%
43,128,00054,030,00060,794,00065,219,00045,258,00000637,0006,447,00017,400,00023,460,00022,380,00037,486,00025,990,00030,747,00036,712,00056,155,00041,484,00037,760,00044,987,000
Net income
13m
-15.10%
-17,966,000-2,426,000-8,021,000-3,655,00034,893,000-707,000-1,066,000-1,421,00012,862,00020,765,000-7,370,00028,888,0003,047,0006,195,00023,828,0005,202,00025,929,00013,491,00015,887,00013,488,000
CFO
23m
+54.83%
-16,263,000-1,661,000-8,433,000-418,000-2,044,000-1,310,000-1,225,000-1,115,0001,344,0005,125,00011,209,0009,643,00019,458,00019,626,00018,536,00019,268,00034,295,0008,202,00014,887,00023,049,000
Dividend
Sep 13, 20240.5625 USD/sh
Earnings
Aug 12, 2025

Profile

SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
URL
https://www.swkhold.com/
IPO date
Sep 22, 1999
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,987
19.14%
37,760
-8.98%
41,484
-26.13%
Cost of revenue
15,893
14,668
26,868
Unusual Expense (Income)
NOPBT
29,094
23,092
14,616
NOPBT Margin
64.67%
61.15%
35.23%
Operating Taxes
4,884
(1,274)
(4,000)
Tax Rate
16.79%
NOPAT
24,210
24,366
18,616
Net income
13,488
-15.10%
15,887
17.76%
13,491
-47.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,014)
(6,327)
(1,138)
BB yield
3.05%
2.84%
0.50%
Debt
Debt current
2,445
Long-term debt
31,412
43,131
33
Deferred revenue
33
Other long-term liabilities
6,568
6,864
13,312
Net debt
24,905
38,580
(3,754)
Cash flow
Cash from operating activities
23,049
14,887
8,202
CAPEX
(138)
(496)
(297)
Cash from investing activities
(10,134)
(48,948)
(43,548)
Cash from financing activities
(12,224)
33,140
(1,361)
FCF
24,260
21,652
18,249
Balance
Cash
5,927
4,503
6,156
Long term investments
580
48
76
Excess cash
4,258
2,663
4,158
Stockholders' equity
(4,131,301)
(4,144,789)
(4,154,704)
Invested Capital
4,457,971
4,475,099
4,450,456
ROIC
0.54%
0.55%
0.43%
ROCE
8.91%
6.99%
4.94%
EV
Common stock shares outstanding
12,451
12,696
12,880
Price
15.86
-9.53%
17.53
-0.62%
17.64
-10.14%
Market cap
197,473
-11.27%
222,561
-2.04%
227,203
-9.82%
EV
222,378
261,141
219,738
EBITDA
29,509
26,002
17,444
EV/EBITDA
7.54
10.04
12.60
Interest
4,685
1,849
340
Interest/NOPBT
16.10%
8.01%
2.33%